VWR Corporation (VWR) Upgraded by BidaskClub to “Sell”
VWR Corporation (NASDAQ:VWR) was upgraded by research analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Friday.
A number of other equities research analysts have also issued reports on VWR. Zacks Investment Research upgraded VWR Corporation from a “hold” rating to a “buy” rating and set a $37.00 price target for the company in a research note on Wednesday, August 2nd. TheStreet upgraded VWR Corporation from a “c” rating to a “b-” rating in a research note on Wednesday, April 19th. Finally, William Blair lowered VWR Corporation from an “outperform” rating to a “market perform” rating in a research note on Friday, May 5th. Three investment analysts have rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the stock. VWR Corporation has an average rating of “Hold” and a consensus price target of $30.50.
VWR Corporation (VWR) traded down 0.03% during trading on Friday, reaching $32.99. The company had a trading volume of 186,276 shares. The firm has a market capitalization of $4.35 billion, a P/E ratio of 30.55 and a beta of 1.19. The firm’s 50-day moving average price is $33.00 and its 200 day moving average price is $30.13. VWR Corporation has a one year low of $24.42 and a one year high of $37.25.
VWR Corporation (NASDAQ:VWR) last issued its quarterly earnings results on Monday, July 31st. The medical research company reported $0.49 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.45 by $0.04. VWR Corporation had a return on equity of 15.54% and a net margin of 3.12%. The business had revenue of $1.18 billion during the quarter, compared to analyst estimates of $1.16 billion. During the same quarter in the prior year, the business posted $0.42 EPS. VWR Corporation’s revenue for the quarter was up 2.2% compared to the same quarter last year. Equities analysts forecast that VWR Corporation will post $1.86 earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Beacon Capital Management purchased a new position in shares of VWR Corporation during the fourth quarter worth $0. FNY Managed Accounts LLC purchased a new position in shares of VWR Corporation during the first quarter worth $100,000. Advisor Group Inc. raised its position in shares of VWR Corporation by 6.2% in the third quarter. Advisor Group Inc. now owns 4,142 shares of the medical research company’s stock worth $117,000 after buying an additional 243 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. raised its position in shares of VWR Corporation by 649.2% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,488 shares of the medical research company’s stock worth $120,000 after buying an additional 3,889 shares during the last quarter. Finally, Legal & General Group Plc raised its position in shares of VWR Corporation by 51.4% in the first quarter. Legal & General Group Plc now owns 4,812 shares of the medical research company’s stock worth $130,000 after buying an additional 1,634 shares during the last quarter.
VWR Corporation Company Profile
VWR Corporation is a provider of product and service solutions to laboratory and production customers. The Company offers a portfolio of branded and private label laboratory products, services and solutions to the life science, general research and applied markets. The Company operates in two segments: Americas and EMEA-APAC.
Receive News & Ratings for VWR Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VWR Corporation and related companies with MarketBeat.com's FREE daily email newsletter.